Apimeds Pharmaceuticals US, Inc. (APUS) — Net Asset Quality Index
Apimeds Pharmaceuticals US, Inc. (APUS) has a Net Asset Quality Index of 89.6% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $141.22 Million minus total liabilities of $14.70 Million yields net assets of $126.52 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read APUS current and long-term liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Apimeds Pharmaceuticals US, Inc. Net Asset Quality Index Over Time (2021–2025)
This chart shows how Apimeds Pharmaceuticals US, Inc.'s Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of March 2026, the index stands at 89.6%, representing net assets of $126.52 Million against total assets of $141.22 Million USD. For live market cap and overall valuation, see market cap of Apimeds Pharmaceuticals US, Inc..
Annual Net Asset Quality Index for Apimeds Pharmaceuticals US, Inc. (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for Apimeds Pharmaceuticals US, Inc. from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check Apimeds Pharmaceuticals US, Inc. (APUS) strategic asset index to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 93.4% | $153.35 Million | $164.18 Million | $10.84 Million | ▲ +10494.9 pp |
| 2024 | -10401.5% | $-1.36 Million | $13.06K | $1.37 Million | ▼ -10409.0 pp |
| 2023 | 7.6% | $31.87K | $422.08K | $390.20K | ▲ +11571.4 pp |
| 2022 | -11563.9% | $-713.61K | $6.17K | $719.78K | ▼ -11425.3 pp |
| 2021 | -138.5% | $-238.48K | $172.17K | $410.65K | — |